U.S. pharma giant copyright scrapped two experimental weight loss tablets very last year—a as soon as-each day pill, lotiglipron, resulting from elevated liver enzymes and a twice-day-to-day pill, danuglipron, on account of robust Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Participate in and win�